Shire's (SHPG) SHP465 Efficacy and Safety Study Met Primary Endpoints in Adults with ADHD - StreetInsider.com

Reuters

Shire's (SHPG) SHP465 Efficacy and Safety Study Met Primary Endpoints in Adults with ADHD StreetInsider.com Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Topline results revealed the study met its primary endpoints for both doses of SHP465 (12.5mg and 37.5mg) administered once daily, indicating superiority over ... UPDATE 1-Shire says ADHD drug meets main goal of studyReuters Shire's stock surges after ADHD drug trial meets key endpointsMarketWatch Shire says ADHD drug meets main goal of studyKFGO all 7 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNGkMzesJ3AVqeJFNMEVGnaVWs8nXg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779143733902&ei=WMJzV7qLBIPO3AGA7oXoDQ&url=http://www.streetinsider.com/Corporate%2BNews/Shires%2B(SHPG)%2BSHP465%2BEfficacy%2Band%2BSafety%2BStudy%2BMet%2BPrimary%2BEndpoints%2Bin%2BAdults%2Bwith%2BADHD/11783949.html
via IFTTT